Showing results (361-370 of 379) with videos related to

Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 TrialPatrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Nature Cell Biology|September 15, 2020
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosisJunwei Hou, Rongce Zhao, Weiya Xia, et al.
Gynecologic Oncology|June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancerRachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Molecular Therapy. Nucleic Acids|September 30, 2021
ERα determines the chemo-resistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressionsYu-Hao He, Ming-Hsin Yeh, Hsiao-Fan Chen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
BMC Public Health|May 5, 2022
An analysis of age-standardized suicide rates in Muslim-majority countries in 2000-2019Bob Lew, David Lester, Kairi Kõlves, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2026
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming MeetingAinhoa Madariaga, Ana Veneziani, Michael Bookman, et al.
Pageof 38